Anti-Obesity Medications

3 Drugs classified under this therapeutic system

CNS Stimulant. Phentermine (as resinate) 15 mg.
CAPS (Sust. Act.):30 X 15. 1 cap. aft.breakf. accord. to instruct.
Tmt. of sev. obesity that has not respond. to appropriate diet- min.
BMI 30 is req.
Ind. as adjun. in  med. monit. comprehen. regimen of wt. reduct. based on exercise, diet (cal. restrict.) and behav. mod.
C/I: Hypersens.
Pulmon. hypertens.
Exist. heart valve abnormalit./ heart murmur.
Mod.-sev. arter.hyperten.
Cerebrovasc. dis.
Sev. card. dis. includ. arrhythm.
Adv. arterioscleros.
Hyperthyroidis.
Agitated states/ history of psychiatr. ill. includ. anorexia nervosa and depres.
Glaucoma
History of drug/alcohol abuse or depend. Co-admin. with drug for weight loss.

Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml.
PRE-FILL. PENS: 5. Init. 0.6 mg dly.
Dose should be incr. to 3.0 mg dly. in
increm. of 0.6 mg with at least one wk.
interv. to improve GI tolerabil. If escal.
to the next dose step is not tolerated
for two consec. wks., consider discont.
tmt. Dly. doses higher than 3.0 mg are
not recomm.
Adults: as adjunct to reduc. cal. diet and
incr. phys. act. for wt. managt. in pts. BMI
30 (obes.), or 27 to < 30 (overwt.) and at
least one comorbidity such as
dysglycaemia (pre-diabet. or type 2
diabet. Mellit.), hypertens., or
dyslipidaemia and who failed wt.
managt. intervent. Tmt. should be
discont. aft. 12 wks. on the 3 mg/day
dose if pts. have not lost at least 5% of
their initial BW. Adolescents (>12 years)
as an adjunct to a healthy nutr. and incr.
phys. act. for wt. managt. in pts. with
BMI=30. Tmt. should be discont. and
re-eval. if pts. have not lost at least 4% of
their BMI or BMI z score after 12 weeks on
the 3 mg/day or max. toler. dose. Re-eval.
should be perf. periodic.
C/I: Hypersens.